Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Pr... ( CAMBRIDGE Mass. Aug. 29 /- Millen...)

Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation

Date:8/29/2007

CAMBRIDGE, Mass., Aug. 29 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation at the Thomas Weisel Partners 2007 Healthcare Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The presentation will review recent events, clinical pipeline updates, and upcoming milestones. The presentation will be delivered at 8:35 a.m. ET on Friday, September 7, 2007 from the Four Seasons Hotel in Boston, MA. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE(R) (bortezomib) for Injection, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company's website is http://www.millennium.com.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.

Contact:

Kyle Kuvalanka

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. OpGen adds Thomas Pyle and James Ogle to board of directors
2. Jellyfish partners for sales tracking technology
3. GE Healthcare partners with UNC on breast cancer imaging research
4. Manufacturing partnership will move into biotech and biomedical spaces
5. Fergus joins Baird Venture Partners, Caden Bio
6. Avolte Venture Partners reaches capital goal
7. NimbleGen partners with UK biotech firm
8. Big pharma seeks Wisconsin biotech partnerships
9. Thompson in partnership to build ethanol plant
10. Johnson Controls partners on car satellite linkup
11. Doyle, WARF announce partnership to lure stem cell companies

Post Your Comments:

(Date:11/5/2009)...on Thursday, November 5, 2009 at 4:30 p.m. Eastern...ewswire-FirstCall/ - OncoGenex Pharmaceuticals, In... today reported unaudited financial results for th..., 2009 and reviewed the Company,s highlights for t...olidated results reflect the operations of OncoGen...

(Date:11/5/2009)...ovember 5, 2009 Senomyx,... proprietary taste receptor-based technologies to ...verage, and ingredient supply industries, today pr...esults for the third quarter ended September 30, 2...rter of 2009, compared to $4.0 million for the thi...

(Date:11/5/2009)... LASIK Surgery and vision correction experts li...actively involved at the recently concluded Americ...ing in San Francisco, California. Dr. Stephen Brin... Davidorf, MD, Dr. Peter Rapoza, MD, Dr. Michael R...owman, MD, Dr. Edward Manche, MD, and Dr. Parag Ma...

(Date:11/4/2009)... Nov. 4 Star Scientifi...e company plans to introduce the CigRx(TM) nutrace...reek Pharmaceuticals, for worldwide marketing and .... (Nasdaq: VTIV). inVentiv Health offers a comple...stage of the product lifecycle, in a range of heal...

[0] OncoGenex Reports Third Quarter 2009 Financial Results [0] SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS [0] Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting [0] Star Scientific Plans Worldwide Marketing and Sales of CigRx(TM) Nutraceutical in Partnership with inVentiv Health

...ncing for Injectable Biopolymer to Repair Weakened...ymphony Medical, Inc., a developer of novel biopol... today that its patented flagship technology, Algi..., successfully treating a 50-year-old male who was...ompany intends to sponsor a clinical study of Algi...

...14 BioVex Inc, a company developing next genera... cancer and infectious disease, announced today th...hase 3 study with OncoVEX (GM-CSF) in previously t...ma had initiated. The study has commenced recruiti...ingdom, Germany and Australia due to open later in...

...PRNewswire-FirstCall/ - Neptune Technologies &....V.NTB) provides guidance for the expected financi...ne-month period ended February 28, 2009. These res... year 2009 now ending on February, 28. , Neptune e...nded February 28, 2009 in the range of $3,400,000 ...

Other Biology Technology:Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 2 Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 3 Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy 4 BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 2 BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 3 BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma 4 Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 2 Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 3 Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 4 Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results 5

Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results

(Date:11/4/2009)..., Calif., Oct. 23 GenVault Corpora...management for genomic discovery, medicine and ide....D., GenVault,s President and CEO, will be present... on October 26th and 27th in La Jolla, CA. ,, D... overview of the company together with recent cust...

(Date:11/4/2009)..., Oct. 27 Global Rainmakers, Inc.,...nced R&D laboratory, today announced that the ...red to actively commercialize its suite of technol...security offerings. ,, During the past four yea...ars to develop and deploy a series of core--but ex...

(Date:11/4/2009)..., Calif., Nov. 4 GenVault Corporat...ody, M.D., Ph.D., has joined its Board of Director... of the Salk Institute, is an acclaimed physician-... the Salk Institute, Dr. Brody served as president...of the National Academy of Engineering and the Ins...

Breaking Biology News(10 mins):GenVault Corporation to Present at the 2009 BIOCOM Investor Conference 2 Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2 Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3 Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 2 Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors 3 National Healthcare Providers Select onFocus epm 28TM 29 To Help Ensure Success on Financial and Strategic Objectives 50341 1 National Healthcare Providers Select onFocus epm 28TM 29 To Help Ensure Success on Financial and Strategic Objectives 50341 2 Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation 26 Analysis 12833 1 Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation 26 Analysis 12833 2 Caliper Life Sciences Introduces Staccato Protein Workstation for Automated Protein Sample Preparation 26 Analysis 12833 3 Depression Anxiety Bad for the Heart 50336 1 Depression Anxiety Bad for the Heart 50336 2 Depression Anxiety Bad for the Heart 50336 3

[0] GenVault Corporation to Present at the 2009 BIOCOM Investor Conference [0] Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality [0] Dr. William Brody, President of the Salk Institute for Biological Studies, Appointed to GenVault's Board of Directors

...ganization (WHO) and the United Nations Children,s...on target to halve deaths from measles, a leading ...r. Global measles deaths have plummeted by 39%, fr.... , The largest reduction occurred in Africa, the...ere estimated measles deaths decreased by 46%. , "...

...ornia scientists working at Los Alamos National La...teria to remediate environmental contamination fro...nd more upon how resistant the bacteria are to che...ity. The results of a recent Laboratory study may ...ad method for cleaning up sites contaminated with ...

...McGill University Health Centre (MUHC), in Montrea... a new study, published in the on-line edition of ...e researchers document a reduction in the growth o...n of the gene. , The new target gene is called met...chers were able to inhibit the function of the gen...

Other Biology News:Measles Deaths Worldwide Drop By Nearly 40% Over Five Years 2 Study uncovers bacteria's worst enemy 2

Measles Deaths Worldwide Drop By Nearly 40% Over Five Years Study uncovers bacteria's worst enemy MUHC researchers make cancer target breakthrough

Heparin Clotting Assay Kit, HEPTEST from AMERICAN DIAGNOSTICA

Bgl I from Takara Mirus Bio

... DNA Polymerase with a proprietary thermostable pr...elity than standard Taq DNA polymerase, Double the...DNA templates >20kb, Concentration: 5U/ul, Applica...g and mutagenesis We are part of Thermo Fisher Sci...

RNA oligos ready-to-use from Thermo Scientific

Biology Products:

Heparin Clotting Assay Kit, HEPTEST from AMERICAN DIAGNOSTICA Bgl I from Takara Mirus Bio Extensor Hi-Fidelity PCR Enzyme from ABgene RNA oligos ready-to-use from Thermo Scientific

Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Pr...( CAMBRIDGE Mass. Aug. 29 /- Millen...)